Abstract
Primary cutaneous B cell lymphomas have a high recurrence rate after treatment with surgery and/or local radiation therapy. Two men are described in whom radiotherapy-relapsing cutaneous B-cell lymphomas were successfully treated with the monoclonal anti-CD20 antibody rituximab. Both patients had a complete response with no recurrence at follow-up at 17 and 24 months for the large B-cell lymphoma of the leg and the follicle centre cell lymphoma, respectively. These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radiotherapy-relapsing primary cutaneous B cell lymphoma.
Original language | English (US) |
---|---|
Pages (from-to) | 46-48 |
Number of pages | 3 |
Journal | Clinical and Experimental Dermatology |
Volume | 30 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2005 |
ASJC Scopus subject areas
- Dermatology